Pre-Open Stock Movers 01/09: (AXNX) (CHS) (DBVT) Higher (TUFN) (BBBY) (AYI) Lower (more...)

January 9, 2020 9:27 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Today's Pre-Open Stock Movers

Tufin (NYSE: TUFN) 33.8% LOWER; sees Q4 total revenue in the range of $29.5 million to $30.1 million, compared to the companys previous guidance of total revenue in the range of $34.0 million to $38.0 million; and non-GAAP operating loss in the range of $1.1 million to $2.6 million, compared to the company's previous guidance of non-GAAP operating profit in the range of $0.0 million to $3.0 million. (Consensus is for EPS of $0.04 on revenue of $36.1 million)

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) 21.4% HIGHER; reported preliminary unaudited revenue of approximately $10 million for the fourth quarter of 2019 as compared to $0.5 million in the prior year period. For the full year ended December 31, 2019, unaudited revenue was approximately $14 million as compared to $0.7 million for all of 2018.

Chico's FAS, Inc. (NYSE: CHS) 19.8% HIGHER; CFO Todd E. Vogensen has resigned, effective January 17, 2020, to accept a CFO position with another company. Also, the company raised Q4 guidance.

DBV Technologies (Nasdaq: DBVT) 15.7% HIGHER; announced positive topline results of the three-year, open-label extension of the Phase III PEPITES trial (PEOPLE) evaluating the long-term efficacy and safety of investigational Viaskin® Peanut in peanut-allergic children ages 4 to 11 years. The results demonstrate long-term clinical benefit as shown by an increase in eliciting dose (ED), which may decrease the chance of reacting to an accidental peanut exposure. After three years, 75.9% (107/141) of patients had increased their ED from baseline, and 51.8% (73/141) of patients reached an ED of at least 1,000 mg peanut protein by year three.

Applied Genetic Technologies Corporation (Nasdaq: AGTC) 13% HIGHER; announced that it plans to release interim six-month data from the expansion group, and an update of enrollment for its ongoing Phase 1/2 clinical trial in patients with X-linked Retinitis Pigmentosa (XLRP) on January 9, 2020. AGTC management will host a conference call and webcast with accompanying slides to review the data beginning at 8:00am Eastern Time on the same date.

Bed Bath & Beyond (NASDAQ: BBBY) 10.9% LOWER; reported Q3 EPS of ($0.38), $0.40 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $2.76 billion versus the consensus estimate of $2.86 billion. Withdraws full-year guidance. Comparable sales in the fiscal 2019 third quarter declined 8.3%. Withdraws guidance.

AZZ, Inc. (NYSE: AZZ) 10.6% HIGHER; reported Q3 EPS of $0.84, $0.03 better than the analyst estimate of $0.81. Revenue for the quarter came in at $291.1 million versus the consensus estimate of $271.69 million. AZZ, Inc. sees FY2020 EPS of $2.60-$2.90, versus the consensus of $2.78. AZZ, Inc. sees FY2020 revenue of $1.02-1.06 billion, versus the consensus of $1.03 billion.

Acuity Brands (NYSE: AYI) 8.7% LOWER; reported Q1 EPS of $2.13, $0.08 worse than the analyst estimate of $2.21. Revenue for the quarter came in at $834.7 million versus the consensus estimate of $874.72 million.

Kohl's (NYSE: KSS) 8.1% LOWER; said it now expects its fiscal 2019 diluted earnings per share to be at the low end of its previously announced guidance range of $4.75 to $4.95.

Mirati Therapeutics, Inc. (Nasdaq: MRTX) 7.8% LOWER; announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering. All of the shares are being offered by Mirati. In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Nabriva Therapeutics plc (NASDAQ: NBRV) 7.3% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of its New Drug Application (NDA) resubmission for marketing approval of CONTEPO (fosfomycin) for injection for the treatment of complicated urinary tract infections (cUTIs).

Helen of Troy (NASDAQ: HELE) 6.5% HIGHER; reported Q3 EPS of $3.12, $0.62 better than the analyst estimate of $2.50. Revenue for the quarter came in at $474.7 million versus the consensus estimate of $446.36 million. Helen of Troy sees FY2020 EPS of $8.90-$9.10, versus the consensus of $8.68. Helen of Troy sees FY2020 revenue of $1.65-1.675 billion, versus the consensus of $1.63 billion.

Snap (NYSE: SNAP) 4.4% HIGHER; upgraded to Outperform at Cowen and Buy at Jefferies.

Tenneco (NYSE: TEN) 4.2% HIGHER; Former Icahn Deputy Presses Co. to Sell or Face Proxy Fight.

TriplePoint Venture Growth BDC Corp. (NYSE: TPVG) 4% LOWER; announced that it has commenced an underwritten offering of 5,000,000 shares of its common stock. In connection with the proposed offering, the Company intends to grant the underwriters for the offering an option to purchase up to an additional 750,000 shares of the Company’s common stock.

AMD (NASDAQ: AMD) 2.5% HIGHER; upgraded to Buy at Mizuho

L Brands, Inc. (NYSE: LB) 1.9% LOWER; expects to report fourth quarter earnings per share of about $1.85 compared to its previous guidance of about $2.00. (*Consensus sees Q4 EPS of $1.97)

Starbucks (NASDAQ: SBUX) 1.7% HIGHER; Barclays upgraded from Equalweight to Overweight with a price target of $107.00.

Goldman Sachs (NYSE: GS) 1.6% HIGHER; upgraded at BofA and Buckingham

Citigroup (NYSE: C) 1.6% HIGHER; eing called a Pick of the Decade at BofA.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Carl Icahn, Goldman Sachs, Citi, Jefferies & Co, Barclays, Cowen & Co, Earnings, Pre-Open Losers, Pre Market Movers, FDA